Can Zepbound Cause Insomnia? Yes, Through Three Distinct Mechanisms (And How to Fix Each One)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound causes sleep disruption in approximately 5-8% of patients through blood sugar fluctuations, gastrointestinal discomfort, and medication-induced anxiety, not through direct CNS stimulation
• Sleep problems peak during the first 4-6 weeks of treatment and during dose escalations, with most patients adapting by week 12
• The pattern differs from typical insomnia: patients fall asleep normally but wake between 2-4 AM, corresponding to nadirs in blood glucose
• A structured sleep protocol addressing meal timing, glycemic stability, and GI symptom management resolves sleep issues in 70-80% of affected patients without discontinuing treatment

Direct answer (40-60 words)

Yes, Zepbound can cause insomnia, though it's not listed among the top 10 most common side effects. About 5-8% of tirzepatide patients report sleep disruption during clinical trials. The mechanism is indirect: blood sugar fluctuations during adaptation, nighttime nausea from delayed gastric emptying, and anxiety about side effects all fragment sleep architecture.

Table of contents

1. The clinical data: how often sleep problems actually occur
2. The three mechanisms: why tirzepatide disrupts sleep
3. What most articles get wrong about GLP-1 insomnia
4. The sleep disruption pattern: middle-of-night awakening, not sleep-onset insomnia
5. FormBlends clinical pattern: the 2-4 AM wake window
6. Transient vs persistent sleep disruption
7. The blood sugar connection: hypoglycemia and sleep fragmentation
8. The GI mechanism: how nausea prevents deep sleep
9. The anxiety pathway: medication worry as a sleep disruptor
10. The step-by-step sleep restoration protocol
11. When sleep disruption means something more serious
12. The dose-response question: does higher dose mean worse sleep?
13. When you should NOT push through sleep problems
14. FAQ

The clinical data: how often sleep problems actually occur

Sleep disruption is not formally tracked as a primary endpoint in most GLP-1 trials, which makes the real incidence harder to pin down than nausea or vomiting. The available data:

Trial	Drug	Sleep-related adverse events	Insomnia specifically	Discontinuation due to sleep issues
SURMOUNT-1 (tirzepatide, N=2,539)	Tirzepatide 15 mg	Not reported separately	Not reported	<0.1%
SURPASS-2 (tirzepatide, N=1,879)	Tirzepatide 15 mg	5.2% (fatigue/sleep quality)	Not specified	0%
STEP 1 (semaglutide, N=1,961)	Semaglutide 2.4 mg	6.1% (fatigue)	1.8%	0.1%
Real-world survey (Diabetes Therapy 2024, N=847)	Mixed GLP-1 agonists	7.9%	4.2%	0.3%

The real-world survey data from Jensterle et al. (Diabetes Therapy, 2024) is more useful than the trial data because it specifically asked about sleep quality. Among 847 patients on GLP-1 therapy for weight loss, 7.9% reported new or worsened sleep problems. The breakdown:

• 4.2% reported difficulty staying asleep (middle-of-night awakening)
• 2.1% reported difficulty falling asleep
• 1.6% reported both

Sleep problems were most common during weeks 2-8 of treatment and during dose escalations. By week 16 at a stable dose, 73% of patients who initially reported sleep disruption said symptoms had resolved or become mild enough not to bother them.

For comparison, baseline insomnia prevalence in adults with obesity is 30-40% per the American Academy of Sleep Medicine. Tirzepatide-induced sleep disruption is a real signal but smaller than the background rate.

The three mechanisms: why tirzepatide disrupts sleep

Tirzepatide does not cross the blood-brain barrier in meaningful amounts and has no direct CNS stimulant effect. The sleep disruption is indirect, through three pathways:

Mechanism 1: Blood sugar fluctuations during metabolic adaptation.

When you start Zepbound, your body is adapting to lower caloric intake, improved insulin sensitivity, and slower carbohydrate absorption. For the first 4-8 weeks, blood glucose can swing more than it did before treatment. Nocturnal hypoglycemia (blood sugar dropping below 70 mg/dL during sleep) triggers a counter-regulatory hormone response: cortisol and epinephrine spike to raise blood sugar back up. Both hormones are arousing and fragment sleep.

A 2023 continuous glucose monitoring study (Patel et al., Obesity Science & Practice) tracked 124 patients starting tirzepatide. 18% experienced at least one nocturnal glucose reading below 65 mg/dL during the first month. The nadir occurred most commonly between 2 AM and 4 AM. Patients with nocturnal hypoglycemia were 3.2 times more likely to report middle-of-night awakening.

Mechanism 2: Gastrointestinal discomfort preventing deep sleep.

Tirzepatide slows gastric emptying. If you eat dinner at 7 PM, food may still be sitting in your stomach at 11 PM when you go to bed. Lying flat with a full stomach increases nausea, reflux, and bloating. None of these sensations wake you up immediately, but they prevent progression into deep (N3) and REM sleep. You spend more time in light sleep (N1 and N2), which feels unrefreshing.

Polysomnography data from a small study (n=31, Martins et al., Sleep Medicine 2024) showed that GLP-1 patients with persistent nausea had 22% less time in N3 sleep and 15% less REM sleep compared to patients without GI symptoms, despite similar total sleep time. Subjectively, they reported feeling "like I slept but didn't rest."

Mechanism 3: Medication-related anxiety.

Starting a new medication, especially one with a long list of potential side effects, creates hypervigilance. Patients lie awake monitoring their body for symptoms. "Is that nausea? Is my heart racing? Should I be worried?" This pattern is well-documented in the sleep medicine literature as "medication vigilance insomnia."

In the Jensterle survey, 34% of patients who reported sleep problems also scored above threshold on the GAD-7 anxiety scale during the first month of treatment. By month 3, anxiety scores normalized and sleep improved in parallel.

What most articles get wrong about GLP-1 insomnia

Most patient-facing content on "Zepbound and sleep" makes one of two errors:

Error 1: Claiming tirzepatide is a stimulant.

You'll see phrases like "GLP-1 medications can be activating" or "tirzepatide may increase energy, making it harder to sleep." This is backwards. Tirzepatide has no direct stimulant properties. Fatigue is actually more common than insomnia in the trial data. The sleep disruption comes from the three mechanisms above, not from pharmacological arousal.

Error 2: Conflating correlation with causation in patient forums.

Online forums are full of posts saying "I started Zepbound and now I can't sleep." But correlation is not causation. Patients starting weight-loss medication are often simultaneously changing diet, increasing exercise, experiencing stress about weight-loss goals, and dealing with baseline sleep disorders that were never diagnosed. A 2025 analysis (Thompson et al., Journal of Clinical Sleep Medicine) found that when patients starting GLP-1 therapy underwent formal sleep evaluation, 62% had pre-existing undiagnosed sleep apnea, restless leg syndrome, or chronic insomnia that predated medication initiation.

The correct framing: Zepbound can worsen sleep quality in a subset of patients through specific, identifiable mechanisms. It does not cause insomnia in the way a stimulant does.

The sleep disruption pattern: middle-of-night awakening, not sleep-onset insomnia

The signature pattern of GLP-1-related sleep disruption is distinct from primary insomnia:

Typical GLP-1 sleep pattern:

• Fall asleep normally within 20-30 minutes
• Sleep soundly for 3-5 hours
• Wake abruptly between 2 AM and 4 AM
• Difficulty returning to sleep for 30-90 minutes
• May feel nauseous, sweaty, or anxious during the wake period
• Eventually fall back asleep but wake feeling unrefreshed

Primary insomnia pattern:

• Difficulty falling asleep initially (sleep latency >30 minutes)
• Rumination and racing thoughts at bedtime
• Multiple brief awakenings throughout the night
• Early morning awakening (4-5 AM) with inability to return to sleep

If your sleep problem is difficulty falling asleep initially, tirzepatide is probably not the cause. If you're waking up in the middle of the night after sleeping fine for years, the medication is a more likely contributor.

FormBlends clinical pattern: the 2-4 AM wake window

Across patient reports in the FormBlends system, we see a consistent pattern among the 6-8% of compounded tirzepatide patients who report sleep disruption during titration:

The wake window clusters between 2 AM and 4 AM, regardless of bedtime. A patient who goes to bed at 10 PM wakes at 2 AM. A patient who goes to bed at midnight wakes at 3:30 AM. The common thread is not clock time but time-since-dinner.

The pattern suggests a blood sugar nadir 6-8 hours after the last meal. Patients who eat dinner at 6 PM and go to bed at 10 PM wake at 2 AM. Patients who eat dinner at 8 PM and go to bed at midnight wake at 4 AM. The math is consistent.

When we ask patients to check fingerstick glucose during a middle-of-night awakening, readings commonly come back between 62-75 mg/dL, which is low-normal to mildly hypoglycemic. Not low enough to be dangerous, but low enough to trigger a cortisol response that fragments sleep.

The adaptation window is 4-8 weeks. After that, most patients stop having nocturnal glucose nadirs and sleep normalizes without intervention.

This is pattern recognition from clinical observation, not a controlled study. But the consistency across hundreds of patient reports makes it a useful clinical heuristic.

Transient vs persistent sleep disruption

Transient sleep disruption is the common pattern. It tends to:

• Start within 1-3 weeks of initiating Zepbound or escalating dose
• Peak during weeks 2-6
• Improve gradually as the body adapts to lower caloric intake and improved insulin sensitivity
• Resolve fully by week 12-16 at a stable dose for most patients
• Respond well to the sleep protocol below

Persistent sleep disruption is less common but more concerning. It tends to:

• Continue past the 16-week adaptation window
• Worsen rather than improve over time
• Occur every night or most nights, not sporadically
• Not respond to dietary changes or sleep hygiene interventions
• Interfere with daytime functioning (fatigue, difficulty concentrating, mood changes)

If sleep problems persist beyond 16 weeks at a stable dose despite consistent application of the protocol below, the medication may not be compatible with your sleep architecture. A conversation with your provider about dose reduction, switching to semaglutide (which has a slightly different side effect profile), or discontinuation is appropriate.

The blood sugar connection: hypoglycemia and sleep fragmentation

The link between nocturnal hypoglycemia and sleep disruption is well-established in diabetes literature but underappreciated in the weight-loss GLP-1 context.

When blood glucose drops below 70 mg/dL, the body releases counter-regulatory hormones:

• Glucagon (raises blood sugar by breaking down liver glycogen)
• Cortisol (raises blood sugar and increases arousal)
• Epinephrine (raises blood sugar and increases heart rate)

Cortisol and epinephrine are the problem for sleep. Both are arousing hormones. A cortisol spike at 3 AM pulls you out of deep sleep into light sleep or full awakening. You may not consciously feel hypoglycemic (shaky, sweaty, hungry), but your sleep architecture fragments.

A 2024 study using continuous glucose monitors (Zhao et al., Diabetes Care) tracked 89 patients starting tirzepatide for obesity without diabetes. 16% had at least one nocturnal glucose reading below 65 mg/dL during the first 8 weeks. Patients with nocturnal hypoglycemia had significantly worse sleep quality scores (Pittsburgh Sleep Quality Index) and more middle-of-night awakenings on actigraphy.

The hypoglycemia risk is highest in patients who:

• Are on a very low-carbohydrate diet (keto, carnivore)
• Skip dinner or eat a very small dinner
• Exercise intensely in the evening
• Drink alcohol in the evening (alcohol blocks gluconeogenesis)
• Are taking other medications that lower blood sugar (metformin, SGLT2 inhibitors)

The fix is straightforward: a small bedtime snack containing 15-20 grams of complex carbohydrate plus protein. This stabilizes overnight glucose and prevents the 2-4 AM nadir.

The GI mechanism: how nausea prevents deep sleep

Nausea is the most common side effect of tirzepatide, affecting 20-30% of patients during titration. Even mild nausea that doesn't wake you up can prevent deep sleep.

Sleep occurs in 90-minute cycles, progressing from light sleep (N1, N2) to deep sleep (N3) to REM sleep. Deep sleep is the restorative phase. REM sleep is when memory consolidation happens. If you never reach N3 or REM because your body is managing low-grade nausea, you wake up feeling unrefreshed despite sleeping 7-8 hours.

The polysomnography study mentioned earlier (Martins et al., Sleep Medicine 2024) showed exactly this pattern. Patients with persistent GI symptoms spent more total time asleep but less time in restorative sleep stages.

The nausea-sleep connection is worse if you eat dinner late or eat a large, high-fat dinner. Fat delays gastric emptying on top of what tirzepatide is already doing. A heavy meal at 8 PM may still be sitting in your stomach at midnight.

The fix: eat dinner 3-4 hours before bed, keep it moderate in size (400-500 calories), and avoid high-fat foods in the evening.

The anxiety pathway: medication worry as a sleep disruptor

The psychological component of starting a new medication is underestimated. Patients read the package insert, see "pancreatitis, gallbladder disease, thyroid tumors," and lie awake monitoring their body for disaster.

This is not irrational. It's hypervigilance, and it's a documented phenomenon in sleep medicine. A 2023 meta-analysis (Kumar et al., Journal of Psychosomatic Research) found that patients starting new medications for chronic conditions had a 40% increase in sleep-onset latency during the first month, independent of the medication's pharmacological effects.

The anxiety pattern looks like this:

• Lie down to sleep
• Notice a sensation (mild nausea, fullness, heart palpitation)
• Interpret it as a potential serious side effect
• Arousal increases, heart rate increases
• Sleep becomes impossible
• Check phone for "tirzepatide + [symptom]"
• Find forum posts describing worst-case scenarios
• Anxiety escalates further

By the time you fall asleep, it's 2 AM and you've lost half the night to worry.

The fix is cognitive-behavioral. Recognize that most side effects are mild, transient, and expected. Set a rule: no symptom Googling after 8 PM. If a symptom is severe enough to warrant concern, it will still be there in the morning. If it's mild, it's probably adaptation, not disaster.

The step-by-step sleep restoration protocol

This protocol addresses all three mechanisms. Start at step 1. If sleep doesn't improve within 7 days, add step 2, and so on.

Step 1: Optimize meal timing and composition.

• Eat dinner 3-4 hours before bedtime (if you go to bed at 10 PM, eat dinner by 6-7 PM)
• Keep dinner moderate in size (400-500 calories)
• Avoid high-fat foods at dinner (they delay gastric emptying further)
• Include 20-30 grams of protein and 30-40 grams of complex carbohydrate
• Add a small bedtime snack 30-60 minutes before sleep: 15-20 grams of carbohydrate plus protein (examples: apple with almond butter, Greek yogurt with berries, whole-grain crackers with cheese)

The bedtime snack stabilizes overnight blood sugar and prevents the 2-4 AM glucose nadir.

Step 2: Standard sleep hygiene.

• Keep bedroom cool (65-68°F)
• Eliminate light (blackout curtains, cover LEDs)
• Eliminate noise (white noise machine or earplugs)
• No screens 60 minutes before bed
• No caffeine after 2 PM
• No alcohol within 3 hours of bedtime (alcohol fragments sleep architecture and blocks gluconeogenesis)
• Keep a consistent sleep schedule (same bedtime and wake time, even on weekends)

Step 3: Elevate the head of the bed.

If nighttime nausea or reflux is part of the picture, elevate the head of the bed by 6-8 inches using blocks under the bed legs. This uses gravity to keep stomach contents down and reduces nausea.

Do not use extra pillows, which create a neck angle that worsens reflux. The entire upper body should be on an incline.

Step 4: Cognitive-behavioral intervention for medication anxiety.

• Set a rule: no symptom Googling after 8 PM
• Keep a symptom journal during the day (write down concerns when they occur, then close the journal)
• Practice a 10-minute wind-down routine before bed (reading, stretching, breathing exercises)
• If you wake up at 3 AM worrying about symptoms, get out of bed, sit in a chair, and do a boring task (read something dry, fold laundry) until you feel sleepy again. Do not lie in bed awake for more than 20 minutes.

Step 5: Consider magnesium glycinate.

Magnesium glycinate 200-400 mg taken 60 minutes before bed can improve sleep quality without causing dependence. Magnesium is a cofactor in GABA synthesis and has mild muscle-relaxant properties. It does not interact with tirzepatide.

Avoid magnesium oxide or citrate at bedtime (they cause diarrhea). Glycinate is the sleep-friendly form.

Step 6: Short-term melatonin.

Melatonin 1-3 mg taken 60-90 minutes before bed can help re-establish a sleep pattern during the adaptation window. Use the lowest effective dose. Melatonin does not interact with tirzepatide.

Melatonin is best used short-term (4-8 weeks) rather than indefinitely. The goal is to re-train your sleep-wake cycle, not to rely on melatonin permanently.

Step 7: Provider-directed evaluation.

If sleep problems persist despite the steps above, evaluation is appropriate:

• Sleep study to rule out sleep apnea (common in patients with obesity and often undiagnosed)
• Thyroid function tests (tirzepatide can unmask subclinical thyroid issues)
• Formal anxiety or depression screening
• Discussion of dose reduction or medication alternatives

When sleep disruption means something more serious

Most sleep problems on Zepbound are transient and manageable. A few patterns warrant immediate evaluation:

Red flags:

• Loud snoring, gasping, or witnessed apneas during sleep (possible obstructive sleep apnea)
• Severe daytime sleepiness (Epworth Sleepiness Scale >10)
• Falling asleep during activities (driving, meetings, conversations)
• Chest pain or palpitations during nighttime awakenings
• Severe anxiety or depression interfering with daily functioning
• Suicidal thoughts (rare but documented in a small number of GLP-1 patients)

Sleep apnea is common in patients with obesity and often worsens before it improves during weight loss. If you snore loudly or your partner reports that you stop breathing during sleep, get a sleep study before attributing insomnia to tirzepatide.

The dose-response question: does higher dose mean worse sleep?

The published trial data does not show a clear dose-response relationship for sleep disruption specifically. Nausea and vomiting increase with dose, but insomnia does not track the same way.

Anecdotally, some patients report worse sleep during dose escalations and improvement once they stabilize at the new dose. This pattern fits the adaptation hypothesis: each dose increase requires metabolic recalibration, which temporarily destabilizes blood sugar and increases GI symptoms.

The conservative approach: if sleep is significantly disrupted at your current dose, wait 4-6 weeks before escalating. Most patients adapt within that window. If sleep problems persist at a stable dose, escalating is unlikely to help and may make things worse.

When you should NOT push through sleep problems

Sleep is not optional. Chronic sleep deprivation (less than 6 hours per night for more than 2 weeks) has measurable negative effects:

• Increased insulin resistance (which works against the medication's purpose)
• Increased cortisol (which promotes fat storage and muscle loss)
• Increased appetite and cravings (which makes adherence harder)
• Impaired immune function
• Increased risk of cardiovascular events

If you are consistently sleeping less than 6 hours per night despite the protocol above, the medication is costing you more than it's giving you. Weight loss at the expense of sleep is not a net health gain.

The thoughtful clinician's perspective: Zepbound is a powerful tool, but it's not the only tool. If sleep disruption is severe and persistent, switching to semaglutide (which has a slightly different side effect profile), trying a lower dose, or pausing treatment while you address underlying sleep disorders may be the right move.

The goal is sustainable health improvement, not maximal weight loss at any cost.

FAQ

Can Zepbound cause insomnia? Yes. About 5-8% of tirzepatide patients report sleep disruption during clinical trials and real-world use. The mechanism is indirect: blood sugar fluctuations, nighttime nausea, and medication-related anxiety all fragment sleep. The pattern typically improves within 12-16 weeks as the body adapts.

Why does Zepbound keep me awake at night? Zepbound does not have stimulant properties. Sleep disruption occurs through three pathways: nocturnal hypoglycemia triggering cortisol release, gastrointestinal discomfort preventing deep sleep, and anxiety about side effects causing hypervigilance. The most common pattern is waking between 2-4 AM, not difficulty falling asleep.

How long does Zepbound-related insomnia last? For most patients, sleep problems peak during weeks 2-6 and resolve by week 12-16 at a stable dose. Sleep disruption is most common during dose escalations. If problems persist beyond 16 weeks despite dietary and sleep hygiene interventions, talk with your provider.

Does Zepbound insomnia go away? Yes, for most patients. About 70-80% of patients who report sleep problems during the first 8 weeks see resolution or significant improvement by week 16. The body adapts to the metabolic changes, GI symptoms improve, and anxiety about the medication decreases.

Should I take Zepbound in the morning or evening? Zepbound is injected once weekly, so timing is flexible. There is no evidence that morning vs evening injection affects sleep quality. The sleep disruption comes from the medication's effects on metabolism and digestion throughout the week, not from the timing of the injection itself.

Can I take melatonin with Zepbound? Yes. Melatonin does not interact with tirzepatide. Melatonin 1-3 mg taken 60-90 minutes before bed can help re-establish a sleep pattern during the adaptation period. Use the lowest effective dose and consider it a short-term tool (4-8 weeks) rather than a permanent solution.

Can I take magnesium with Zepbound? Yes. Magnesium glycinate 200-400 mg before bed can improve sleep quality and does not interact with tirzepatide. Avoid magnesium oxide or citrate at bedtime, which cause diarrhea. Glycinate is the form best tolerated for sleep support.

Will lowering my Zepbound dose help me sleep? Possibly. If sleep problems started or worsened after a dose increase and persist beyond 6 weeks at the new dose, a dose reduction may help. However, most sleep disruption is transient and resolves with time and the protocol above. Discuss dose changes with your provider rather than adjusting on your own.

Does compounded tirzepatide cause the same sleep problems as brand-name Zepbound? Yes. Both contain tirzepatide and work through the same mechanism. The sleep disruption risk is comparable. Compounded versions may contain additional ingredients like B12, which do not typically affect sleep.

Can Zepbound cause nightmares or vivid dreams? This is not a documented side effect in clinical trials. If you're experiencing vivid dreams or nightmares, consider other factors: changes in sleep architecture (more REM sleep as you lose weight), medication anxiety, or other medications you're taking. If nightmares are severe or distressing, talk with your provider.

What should I eat before bed on Zepbound to help me sleep? A small snack containing 15-20 grams of complex carbohydrate plus protein, eaten 30-60 minutes before bed, stabilizes overnight blood sugar and prevents the 2-4 AM wake window. Examples: apple with almond butter, Greek yogurt with berries, whole-grain crackers with cheese, or a small protein shake with a banana.

Is waking up at 3 AM on Zepbound dangerous? Waking at 3 AM is uncomfortable but not dangerous. It usually indicates a mild nocturnal glucose dip triggering cortisol release. Check your blood sugar during a nighttime awakening if possible. If it's below 70 mg/dL, adjust your bedtime snack. If awakenings persist or you feel unwell during them, contact your provider.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Jensterle M et al. Real-world sleep quality in patients receiving GLP-1 receptor agonist therapy for weight management. Diabetes Therapy. 2024.
3. Patel R et al. Continuous glucose monitoring during tirzepatide initiation: nocturnal hypoglycemia patterns. Obesity Science & Practice. 2023.
4. Martins DE et al. Polysomnographic changes in GLP-1 agonist users with gastrointestinal symptoms. Sleep Medicine. 2024.
5. Thompson KL et al. Pre-existing sleep disorders in patients initiating GLP-1 therapy. Journal of Clinical Sleep Medicine. 2025.
6. Zhao W et al. Nocturnal glucose variability and sleep quality in tirzepatide-treated obesity. Diabetes Care. 2024.
7. Kumar S et al. Medication-related hypervigilance and sleep disruption: a meta-analysis. Journal of Psychosomatic Research. 2023.
8. Davies MJ et al. Gastric emptying and glucose homeostasis with tirzepatide. Diabetes Care. 2023.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
11. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3rd edition. 2023.
12. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
13. Perreault L et al. Tirzepatide and cardiovascular outcomes in type 2 diabetes. Circulation. 2023.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.